Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease
Abstract Maintaining consistent levodopa benefits while simultaneously controlling dyskinesia can be difficult. Recently, an amantadine delayed release/extended release (DR/ER) formulation (Gocovri®) indicated for dyskinesia received additional FDA approval as an adjunct to levodopa for the treatmen...
محفوظ في:
| المؤلفون الرئيسيون: | , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Nature Portfolio
2022-03-01
|
| سلاسل: | npj Parkinson's Disease |
| الوصول للمادة أونلاين: | https://doi.org/10.1038/s41531-022-00291-1 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|